Actively Recruiting
A Study of VET3-TGI in Patients With Solid Tumors
Led by KaliVir Immunotherapeutics · Updated on 2026-04-07
60
Participants Needed
7
Research Sites
171 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with atezolizumab in patients with solid tumors (STEALTH-001).
CONDITIONS
Official Title
A Study of VET3-TGI in Patients With Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have pathologically confirmed advanced, unresectable, or metastatic solid tumors including breast, bladder, cervical, colorectal, esophageal, head and neck, renal, ovarian, sarcoma, thymoma, or uterine carcinoma
- Failed, intolerant to, or refused curative treatment options such as molecularly targeted agents, immunotherapy, or chemotherapy
- Have measurable disease according to RECIST 1.1 criteria
- Have at least one tumor suitable for safe intratumoral injections and/or biopsies
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Demonstrate adequate organ function
- Willing to comply with all study procedures and post-treatment care instructions
You will not qualify if you...
- Have not completed required washout periods from prior systemic therapies
- Require anti-platelet or anti-coagulant therapy that cannot be safely stopped for biopsies or injections
- Have untreated or incompletely treated central nervous system metastases or carcinomatous meningitis
- Have a prior history of myocarditis
- Have known HIV/AIDS or active hepatitis B or C infection
- Are receiving high-dose immunosuppressive medications or have significant immunodeficiency such as transplant recipients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Actively Recruiting
2
UC Irvine Health
Orange, California, United States, 92868
Actively Recruiting
3
University of Miami
Miami, Florida, United States, 33136
Actively Recruiting
4
Community Health Network
Indianapolis, Indiana, United States, 46250
Actively Recruiting
5
UPMC- Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232
Actively Recruiting
6
Mary Crowley Cancer Research
Dallas, Texas, United States, 75230
Actively Recruiting
7
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
A
Adina Pelusio
CONTACT
J
James Burke, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here